$33.47
1.06% today
Nasdaq, Feb 05, 04:47 pm CET
ISIN
US30161Q1040
Symbol
EXEL

Exelixis, Inc. Stock price

$33.12
-0.08 0.24% 1M
+9.60 40.82% 6M
-0.18 0.54% YTD
+11.72 54.77% 1Y
+14.33 76.26% 3Y
+15.52 88.18% 5Y
+31.27 1,690.27% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.24 0.73%
ISIN
US30161Q1040
Symbol
EXEL
Sector
Industry

Key metrics

Market capitalization $9.46b
Enterprise Value $8.46b
P/E (TTM) P/E ratio 21.11
EV/FCF (TTM) EV/FCF 19.56
EV/Sales (TTM) EV/Sales 4.07
P/S ratio (TTM) P/S ratio 4.54
P/B ratio (TTM) P/B ratio 4.16
Revenue growth (TTM) Revenue growth 17.31%
Revenue (TTM) Revenue $2.08b
EBIT (operating result TTM) EBIT $608.28m
Free Cash Flow (TTM) Free Cash Flow $432.69m
Cash position $1.19b
EPS (TTM) EPS $1.57
P/E forward 19.14
P/S forward 4.37
EV/Sales forward 3.91
Short interest 6.81%
Show more

Is Exelixis, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Exelixis, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

24 Analysts have issued a Exelixis, Inc. forecast:

13x Buy
54%
9x Hold
38%
2x Sell
8%

Analyst Opinions

24 Analysts have issued a Exelixis, Inc. forecast:

Buy
54%
Hold
38%
Sell
8%

Financial data from Exelixis, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
2,082 2,082
17% 17%
100%
- Direct Costs 78 78
17% 17%
4%
2,004 2,004
17% 17%
96%
- Selling and Administrative Expenses 462 462
6% 6%
22%
- Research and Development Expense 906 906
20% 20%
44%
636 636
694% 694%
31%
- Depreciation and Amortization 28 28
29% 29%
1%
EBIT (Operating Income) EBIT 608 608
1,383% 1,383%
29%
Net Profit 467 467
407% 407%
22%

In millions USD.

Don't miss a Thing! We will send you all news about Exelixis, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Exelixis, Inc. Stock News

Neutral
Business Wire
11 days ago
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from an expansion cohort of the phase 1b/2 STELLAR-001 trial evaluating zanzalintinib alone or in combination with atezolizumab (Tecentriq®) in patients with previously-treated metastatic colorectal cancer (CRC). The findings will be presented during Poster Session C: Cancers of the Colon, Rectum and Anus, a...
Neutral
Business Wire
12 days ago
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic neuroendocrine tumors (epNET) arising in the gastrointestinal (GI) tract. The analysis showed cabozantinib was associated with an improvement in progression-free survival (PFS) compared with placebo in patients wi...
Positive
FXEmpire
14 days ago
Shares of oncology company Exelixis, Inc. (EXEL) gaining on rising revenue, pipeline progress.
More Exelixis, Inc. News

Company Profile

Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA.

Head office United States
CEO Michael Morrissey
Employees 1,310
Founded 1994
Website www.exelixis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today